Cordis goes back to PRISON
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis' drug-eluting Cypher stent is associated with an in-stent restenosis rate of 7% compared to 36% with the Bx Velocity stent in the 200-patient randomized PRISON II trial comparing the stents in patients with chronic total occlusions, according to principal investigator Maarten Suttorp, MD, PhD, St. Antonius Hospital, The Netherlands. Cypher also had a lower target lesion revascularization rate than the bare-metal stent (4% vs. 19%) and a lower MACE rate (4% vs. 20%)...